Genta, Inc. (GNTA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA)

GNTA 1.900

-1.3%

2:37 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NRugg who wrote (1754)	2/15/2004 9:47:38 AM
From: Art Bechhoefer	of 1870

Significant revenue from Genasense will depend on how soon Genta's partner Aventis will be able to manufacture and market the drug in quantity--perhaps within a matter of months after approval. However, the real problem is that Genta may have to raise money before that time. The only way they can do this is to work out some arrangement with Aventis or other interested companies, or issue more stock, which will dilute future earnings. The good news is that approval of Genasense as part of a treatment for melanoma will pave the way for its use in other applications, such as metastizing breast cancer. Art

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next